2.5 REFERENCES
Adibhatla and Hatcher (2006) Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med 40:376-387
Baldus et al. (2003) Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes Circulation108:1440-1445
Beckman et al. (2002) Diabetes and atherosclerosis: Epidemiology, Pathophysiology, and management. JAMA287:2570-2581
Bhakdi et al. (2004) Beyond cholesterol: the enigma of atherosclerosis revisited. Thromb Haemostasis 91:639-645
Clarke et al. (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med361:2518-2528
Empana et al. (2003) Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? European Heart Journal 24:1903-1911
Grundy et al. (2002) Prevention Conference VI: Diabetes and Cardiovascular Disease. Circulation 105:2231-2239
Holvoet et al. (1996) Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemostasis 76:663-669
Holvoet et al. (1998) Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98:1487-1494
Holvoet et al. (2001) Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.Arterioscler Thromb Vasc Biol 21:844-848.
Holvoet et al. (2002) Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the health, aging, and body composition study. Arterioscler Thromb Vasc Biol23:1444-1448
Holvoet (2004) Oxidized LDL and coronary heart disease. Acta Cardiol 59: 479-484
Huang et al. (1999) Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 19:2640-2647
Hulthe J, Fagerberg B, Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol. 2002; 22:1162-1167
Hörkkö et al. (1999) Monoclonal autoantibodies specific for oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 103:117-128
Itabe et al. (1994) A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 269:15274-15279
Johnston et al. (2006) Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers. Am J Cardiol 97:640-645
Johnston et al. (2006) Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. Int J Cardiol 113:167-173
Kamstrup et al. (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA301:2331-2339
Kopprasch et al. (2002) In Vivo Evidence for Increased Oxidation of Circulating LDL in Impaired Glucose Tolerance.Diabetes 51:3102-3106
Libby (2002) Atherosclerosis: the new view. Sci Am 286:46-55
Liu et al. (2004) Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyper-lipidemia families. Arterioscler Thromb Vasc Biol 24:1492-1497
Meisinger et al. (2005) Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 112:651-657
Ndrepepa et al. (2008) Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest 38:90-96
Palinski et al. (1996) Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest98:800-814
Rhodas et al. (1986). Lp(a) Lipoprotein as a risk factor for myocardial infarction. JAMA 256:2540–2544
Rosengren et al. (1990) Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 301:1248–1251
Scheffer et al. (2003) Associations of LDL with in vitro oxidizability and plasma levels of in vivo oxidized LDL in Type 2 diabetic patients. Diabetic Medicine 20:563-567
Sigurdardottir et al. (2002) Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Internal Med 252:440-447
Thanassoulis and O'Donnell (2009) Mendelian randomization: nature's randomized trial in the post-genome era.JAMA 2009 301:2386-2388
Wallenfeldt et al. (2002) Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Internal Medicine 256:413-420
Young and McEneny (2001) Lipoprotein oxidation and atherosclerosis. Biochem Soc Trans 29:358-362
Back to Atherosclerosis and cardiovascular complications
